AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 1 - (NewsRx.com & NewsRx.net) -- Researchers have developed a DNA prime-MVA boost HIV vaccine tailored for eastern and central Africa.
According to a study from England, "For the development of human immunodeficiency virus type 1 (HIV-1) vaccines, traditional approaches inducing virus-neutralizing antibodies have so far failed. Thus the effort is now focused on elicitation of cellular immunity. We are currently testing in clinical trials in the United Kingdom and East Africa a T-cell vaccine consisting of HIV-1 clade A Gag-derived immunogen HIVA delivered in a prime-boost regimen by a DNA plasmid and modified vaccinia virus Ankara (MVA)."
"Here, we describe engineering and preclinical development of a second immunogen RENTA, which will be used in combination with the present vaccine in a four-component DNA/HIVA-RENTA prime-MVA/HIVA-RENTA boost formulation," said J. P. Nkolola and colleagues at the Weatherall Institute of Molecular Medicine. "RENTA is a fusion protein derived from consensus HIV clade A sequences of Tat, reverse transcriptase, Nef and gp41."
The investigators concluded, "We inactivated the natural biological activities of the HIV ...
Source: HighBeam Research, DNA prime-MVA boost HIV vaccine tailored for eastern and central...